Biotech Values

[DewDiligence]

MDVN moves closer to a deal with SNY (or another suitor):

http://finance.yahoo.com/news/medivation-enters-confidentiality-agreements-including-201500382.html

Medivation, Inc. today announced that it has entered into confidentiality agreements with a number of parties that have expressed interest in exploring a potential transaction and demonstrated that interest to the Board of Directors’ satisfaction [i.e. a sufficiently high starting price]. The [Sanofi] proposal, which was conditional upon the execution of a confidentiality agreement and the receipt of information, was for $58.00 per share in cash plus a Contingent Value Right for talazoparib sales representing a potential payment in 2022 of a maximum of $3.00 per share.